Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD.

Challenge

A substantial proportion of IBD patients discontinue biologic therapy within 12 months, but the real-world predictors of biologic discontinuation—separately for CD and UC—had not been characterized in a large prospective US cohort, limiting understanding of durability challenges in routine care.

Solution

The TARGET-IBD registry was used to analyze time to biologic discontinuation and its predictors across CD and UC patients using Kaplan-Meier survival analysis and multivariable Cox proportional hazards regression, funded by AbbVie and Bristol Myers Squibb.

Impact

Establishing that nearly one-third of IBD patients discontinue biologic therapy—with secondary loss of response as the leading driver—provides real-world evidence of the durability gap that next-generation IBD therapies must address, directly informing drug development programs and prescriber strategies for optimizing biologic durability.